Phase II study to assess the efficacy, safety and tolerability of the mitotic spindle kinesin inhibitor AZD4877 in patients with recurrent advanced urothelial cancer

Investigational New Drugs

Volumn 31, Issue 4, 2013, Pages 1001-1007

  Jones, Robert ^a,p   Vuky, Jacqueline ^b   Elliott, Tony ^c   Mead, Graham ^d   Arranz, José Angel ^e   Chester, John ^f   Chowdhury, Simon ^g   Dudek, Arkadiusz Z ^h   Müller Mattheis, Volker ⁱ   Grimm, Marc Oliver ^j   Gschwend, Jürgen E ^k   Wülfing, Christian ^l   Albers, Peter ^m   Li, Jianguo ⁿ   Osmukhina, Anna ⁿ   Skolnik, Jeffrey ⁿ   Hudes, Gary ^o  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c CHRISTIE HOSPITAL   (United Kingdom)

^d SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^e HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^f ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^g GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^h UNIVERSITY OF MINNESOTA   (United States)

ⁱ HEINRICH HEINE UNIVERSITY   (Germany)

^j DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^k TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^l UNIVERSITY OF MÜNSTER   (Germany)

^m UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

ⁿ ASTRAZENECA   (United Kingdom)

^o FOX CHASE CANCER CENTER   (United States)

^p BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

more..

Author keywords

AZD4877; Bladder cancer; Eg5; Mitotic kinesin inhibitor; Objective tumor response; Phase II; Transitional cell carcinoma; Urothelial cancer

Indexed keywords

ANTINEOPLASTIC AGENT; AZD 4877; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ACUTE HEART INFARCTION; ADULT; ADVANCED CANCER; ADVERSE OUTCOME; AGED; ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; BLADDER CARCINOMA; CANCER CHEMOTHERAPY; CANCER MORTALITY; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONGESTIVE HEART FAILURE; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FLU LIKE SYNDROME; HUMAN; HYPERGLYCEMIA; INFUSION RELATED REACTION; INSOMNIA; KIDNEY PELVIS CARCINOMA; LETHARGY; LEUKOCYTE COUNT; LEUKOPENIA; MALE; MAXIMUM PLASMA CONCENTRATION; METASTASIS; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECURRENT CANCER; SIDE EFFECT; THROMBOCYTOPENIA; THRUSH; TRANSITIONAL CELL CARCINOMA; TREATMENT RESPONSE; URETER CARCINOMA; URETHRA CARCINOMA; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BENZAMIDES; DEMOGRAPHY; FEMALE; HUMANS; KINESIN; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PYRIMIDINONES; SPINDLE APPARATUS; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 84880924613     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-013-9926-y     Document Type: Article

References (34)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61:69-90
2. Whitmore WF Jr (1983) Management of invasive bladder neoplasms. Semin Urol 1:34-41
3. Svatek RS, Siefker-Radtke A, Dinney CP (2009) Management of metastatic urothelial cancer: the role of surgery as an adjunct to chemotherapy. Can Urol Assoc J 3:S228-S231
4. von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ, Bodrogi I, Albers P, Knuth A, Lippert CM, Kerbrat P, Sanchez RP, Wersall P, Cleall SP, Roychowdhury DF, Tomlin I, Visseren-Grul CM, Conte PF (2000) Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 18:3068-3077
5. Bellmunt J, Theodore C, Demkov T, Komyakov B, Sengelov L, Daugaard G, Caty A, Carles J, Jagiello-Gruszfeld A, Karyakin O, Delgado FM, Hurteloup P, Winquist E, Morsli N, Salhi Y, Culine S, von der Maase H (2009) Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol 27:4454-4461
6. Wittmann T, Hyman A, Desai A (2001) The spindle: a dynamic assembly of microtubules and motors. Nat Cell Biol 3:E28-E34
7. Valentine MT, Fordyce PM, Block SM (2006) Eg5 steps it up! Cell Div 1:31
8. Mayer TU, Kapoor TM, Haggarty SJ, King RW, Schreiber SL, Mitchison TJ (1999) Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen. Science 286:971-974
9. DeBonis S, Skoufias DA, Lebeau L, Lopez R, Robin G, Margolis RL, Wade RH, Kozielski F (2004) In vitro screening for inhibitors of the human mitotic kinesin Eg5 with antimitotic and antitumor activities. Mol Cancer Ther 3:1079-1090
10. Sakowicz R, Finer JT, Beraud C, Crompton A, Lewis E, Fritsch A, Lee Y, Mak J, Moody R, Turincio R, Chabala JC, Gonzales P, Roth S, Weitman S, Wood KW (2004) Antitumor activity of a kinesin inhibitor. Cancer Res 64:3276-3280
11. Lad L, Luo L, Carson JD, Wood KW, Hartman JJ, Copeland RA, Sakowicz R (2008) Mechanism of inhibition of human KSP by ispinesib. Biochemistry 47:3576-3585
12. Cox CD, Coleman PJ, Breslin MJ, Whitman DB, Garbaccio RM, Fraley ME, Buser CA, Walsh ES, Hamilton K, Schaber MD, Lobell RB, Tao W, Davide JP, Diehl RE, Abrams MT, South VJ, Huber HE, Torrent M, Prueksaritanont T, Li C, Slaughter DE, Mahan E, Fernandez-Metzler C, Yan Y, Kuo LC, Kohl NE, Hartman GD (2008) Kinesin spindle protein (KSP) inhibitors. 9. Discovery of (2S)-4-(2,5- difluorophenyl)-n-[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]-2-(hydrox ymethyl)-N-methyl-2-phenyl-2,5-dihydro-1H-pyrrole-1-carboxamide (MK-0731) for the treatment of taxane-refractory cancer. J Med Chem 51:4239-4252
13. Shahin MS, Braly P, Rose P, Malpass T, Bailey H, Alvarez RD, Hodge J, Bowen C, Buller R (2007) A Phase II, open-label study of ispinesib (SB-715992) in patients with platinum/taxane refractory or resistant relapsed ovarian cancer. J Clin Oncol 25(18S):abst 5562
14. Philco M, Falcon S, Gomez H, Escandon R, Saikali K, Wolff A (2008) A phase I-II open-label trial of ispinesib on an alternate dosing schedule in chemotherapy-naive patients with locally advanced or metastatic breast cancer (MBC). J Clin Oncol 26(15S):abst 1143
15. El-Khoueiry AB, Iqbal S, Singh DA, D'Andre S, Ramanathan RK, Shibata S, Yang DY, Lenz HJ, Synold T, Gandara DR (2006) A randomized Phase II non-comparative study of ispinesib given weekly or every three weeks in metastatic colorectal cancer. A California Cancer Consortium Study (CCC-P). J Clin Oncol 24(18S):abst 3595
16. Lee RT, Beekman KE, Hussain M, Davis NB, Clark JI, Thomas SP, Nichols KF, Stadler WM (2008) A University of Chicago consortium phase II trial of SB-715992 in advanced renal cell cancer. Clin Genitourin Cancer 6:21-24
17. Pinzon-Ortiz MC, Cao A, Sheehy A, Pablo L, McEachern K, Hylander-Gans L, Wu K, Reimer C, Morosini D, McCoon P, Huszar D (2010) Characterization of the kinesin spindle protein inhibitor AZD4877. Proc Am Assoc Cancer Res 51:abst 4429
18. Shah JB, Marquis LM, Svatek RS, Papadopoulos JN, Siefker-Radtke A, Dinney CP, McConkey DJ (2009) The mitotic spindle apparatus inhibitor AZD4877 holds promise as a novel therapeutic option against human bladder cancer. ASCO Genitourinary Cancers Symposium, Orlando, FL, p abst 254
19. Infante JR, Kurzrock R, Spratlin J, Burris HA, Eckhardt SG, Li J, Wu K, Skolnik JM, Hylander-Gans L, Osmukhina A, Huszar D, Herbst RS (2012) A Phase I study to assess the safety, tolerability, and pharmacokinetics of AZD4877, an intravenous Eg5 inhibitor in patients with advanced solid tumors. Cancer Chemother Pharmacol 69:165-172
20. Stephenson JJ, Lewis N, Martin JC, Ho A, Li J, Wu K, Pace L, Eder JP, Schwartz GK (2008) Phase I multicenter study to assess the safety, tolerability, and pharmacokinetics of AZD4877 administered twice weekly in adult patients with advanced solid malignancies. J Clin Oncol 26(15S):abst 2516
21. Therasse P (2002) Measuring the clinical response. What does it mean? Eur J Cancer 38:1817-1823
22. AstraZeneca. Global Policy: Bioethics. 2011. Available at: http://www.astrazeneca.com/Responsibility/Code-policies-standards/ Our-global-policies.
23. Loehrer PJ Sr, Einhorn LH, Elson PJ, Crawford ED, Kuebler P, Tannock I, Raghavan D, Stuart-Harris R, Sarosdy MF, Lowe BA (1992) A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 10:1066-1073
24. Lee CW, Belanger K, Rao SC, Petrella TM, Tozer RG, Wood L, Savage KJ, Eisenhauer EA, Synold TW, Wainman N (2008) A Phase II study of ispinesib (SB-715992) in patients with metastatic or recurrent malignant melanoma: a National Cancer Institute of Canada Clinical Trials Group trial. Investig New Drugs 26:249-255
25. Knox JJ, Gill S, Synold T, Biagi JJ, Major P, Feld R, Cripps C, Wainman N, Eisenhauer E, Seymour L (2008) A phase II and pharmacokinetic study of SB-715992, in patients with metastatic hepatocellular carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG IND.168). Investig New Drugs 26:265-272
26. Tang PA, Siu LL, Chen EX, Hotte SJ, Chia S, Schwarz JK, Pond GR, Johnson C, Colevas AD, Synold TW, Vasist LS (2008) Phase II study of ispinesib in recurrent or metastatic squamous cell carcinoma of the head and neck. Investig New Drugs 26:257-264
27. Kantarjian HM, Padmanabhan S, Stock W, Tallman MS, Curt GA, Li J, Osmukhina A, Wu K, Huszar D, Borthukar G, Faderl S, Garcia-Manero G, Kadia T, Sankhala K, Odenike O, Altman JK, Minden M (2012) Phase I/II multicenter study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD4877 in patients with refractory acute myeloid leukemia. Investig New Drugs 30:1107-1115
28. Culine S, Theodore C, De Santis M, Bui B, Demkow T, Lorenz J, Rolland F, Delgado FM, Longerey B, James N (2006) A Phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen. Br J Cancer 94:1395-1401
29. Albers P, Park SI, Niegisch G, Fechner G, Steiner U, Lehmann J, Heimbach D, Heidenreich A, Fimmers R, Siener R (2011) Randomized phase III trial of 2nd line gemcitabine and paclitaxel chemotherapy in patients with advanced bladder cancer: short-term versus prolonged treatment [German Association of Urological Oncology (AUO) trial AB 20/99]. Ann Oncol 22:288-294
30. Niegisch G, Fimmers R, Siener R, Park SI, Albers P (2011) Prognostic factors in second-line treatment of urothelial cancers with gemcitabine and paclitaxel (German Association of Urological Oncology trial AB20/99). Eur Urol 60:1087-1096
31. Esaki T, Seto T, Ariyama H, Arita S, Fujimoto C, Tsukasa K, Kometani T, Nosaki K, Hirai F, Yagawa K (2011) Phase I study to assess the safety, tolerability and pharmacokinetics of AZD4877 in Japanese patients with solid tumors. Arch Drug Inf 4:23-31
32. Park SB, Krishnan AV, Lin CS, Goldstein D, Friedlander M, Kiernan MC (2008) Mechanisms underlying chemotherapy-induced neurotoxicity and the potential for neuroprotective strategies. Curr Med Chem 15:3081-3094
33. Sarli V, Giannis A (2008) Targeting the kinesin spindle protein: basic principles and clinical implications. Clin Cancer Res 14:7583-7587
34. Woessner R, Tunquist B, Lemieux C, Chlipala E, Jackinsky S, Dewolf W Jr, Voegtli W, Cox A, Rana S, Lee P, Walker D (2009) ARRY-520, a novel KSP inhibitor with potent activity in hematological and taxane-resistant tumor models. Anticancer Res 29:4373-4380